Inhibikase Therapeutics to Announce Q2 2024 Financials on Aug 14, 2024

Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics for Parkinson's disease and related conditions, has announced it will release its financial results for the second quarter ending June 30, 2024, on August 14, 2024, after U.S. market hours. The company's announcement will be followed by a conference call and webcast scheduled for 8:00 a.m. ET on August 15, 2024. During this event, Inhibikase Therapeutics will provide a corporate update and discuss its financial performance. Interested parties can access the conference call by dialing specific numbers for U.S. and international participants.

Inhibikase Therapeutics is headquartered in Atlanta, Georgia, with additional offices in Lexington, Massachusetts. The company is dedicated to creating treatments for Parkinson's disease and related disorders, focusing on neurodegeneration. Its leading program, risvodetinib, is an Abelson Tyrosine Kinase (c-Abl) inhibitor designed to treat Parkinson's both within the brain and in other parts of the body. The company's pipeline targets Parkinson's-related disorders affecting the brain and gastrointestinal tract, as well as rare diseases associated with Parkinson's such as Multiple System Atrophy.

One of the innovative drug delivery technologies being developed by Inhibikase includes IkT-001Pro, a prodrug form of the anticancer agent imatinib mesylate. The company believes this version will offer an improved patient experience with fewer side effects during dosing. Additionally, Inhibikase's RAMP™ medicinal chemistry program has identified several follow-on compounds to risvodetinib, which may be applicable to other cognitive and motor function diseases of the brain.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!